MP29-02

DRUG2 trials

Sponsors

Meda Pharmaceuticals, University Hospital, Ghent

Conditions

Bioavailability StudySeasonal Allergic Rhinitis

Phase 3

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

CompletedNCT00660517

Meda PharmaceuticalsSeasonal Allergic Rhinitis

Start: 2007-12-31End: 2008-04-30Updated: 2012-07-27

Unknown Phase

Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate

WithdrawnNCT02883439

University Hospital, GhentBioavailability Study

Start: 2016-08-31End: 2020-03-31Updated: 2021-07-13

Related Papers

A new allergic rhinitis therapy (MP29‐02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies

Clinical and Translational Allergy2015-06-261 citations

Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device.

2010-08-0188 citations